Article

Current Status and Significance of Additional Vaccination with COVID-19 Vaccine in Japan – Consideration from Antibody Levels from Hybrid Immunity and Public Perception

2024-11-07

Abstract excerpt

This report examines the evolving role of Coronavirus Disease 2019 (COVID-19) vaccination in Japan, especially in light of reduced public concern following the reclassification of COVID-19 as a Category 5 infectious disease in May 2023. With over half of the population estimated to have hybrid immunity from prior infections and vaccinations, this report evaluates the necessity and frequency of additional booster d...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: b41d8600-01b6-5ac3-a287-51c12d4570f0
DOI: 10.20944/preprints202411.0555.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Current Status and Significance of Additional Vaccination with COVID-19 Vaccine in Japan – Consideration from Antibody Levels from Hybrid Immunity and Public PerceptionDOI 10.20944/preprints202411.0555.v1Read

COVID-19 and COVID-19 Vaccine in Japan—A Review from a General Physician's PerspectiveSemantic proximity Read

Risk of COVID-19 after Natural Infection or VaccinationSemantic proximity Read

COVID-19 vaccinations: The unknowns, challenges, and hopes.Semantic proximity Read

Humoral Immunity and Transcriptome Differences of COVID-19 Inactivated Vaccine and Protein Subunit Vaccine as Third Booster Dose in HumanSemantic proximity Read

A review of leading COVID-19 vaccines, the quest for immune protection, and its key challenges. Part 3: Covid-19 vaccines – Key challenges and translational scienceSemantic proximity Read

Hybrid immunity improves the immune response after fourth Covid-19 vaccine dose in individuals with medical conditions predisposing to severe Covid-19Semantic proximity Read

An Immunobridging study to evaluate the neutralizing antibody titer in adults immunized with two doses of either ChAdOx1-nCov-19 (AstraZeneca) or MVC-COV1901Semantic proximity Read

Immunogenicity and safety of the homogenous booster shot of a recombinant fusion protein vaccine (V-01) against COVID-19 in healthy adult participants primed with a two-dose regimenSemantic proximity Read

Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccineSemantic proximity Read

Effect of Vaccine Booster, Vaccine Type, and Hybrid Immunity on Humoral and Cellular Immunity Against SARS-CoV-2 Ancestral Strain and Omicron Variant Sublineages BA.2 and BA.5 Among Older Adults with Comorbidities: An Observational StudySemantic proximity Read

Humoral and cellular immune durability of different COVID-19 vaccine platforms following homologous/heterologous boosters: one-year post vaccinationSemantic proximity Read

Efficacy Estimates for Various COVID-19 Vaccines: What we Know from the Literature and ReportsSemantic proximity Read